Old Web
English
Sign In
Acemap
>
authorDetail
>
S. Haemmerle
S. Haemmerle
Novartis
Dose-ranging study
Secukinumab
Psoriasis
Placebo
Medicine
3
Papers
292
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis.
2021
medRxiv
Ann-Marie Mallon
D. A. Haering
F. Dahlke
P. Aarden
S. Afyouni
D. Delbarre
K. El Emam
H. Ganjgahi
S Gardiner
C. H. Kwok
D.M. West
E. Straiton
S. Haemmerle
A. Huffman
T. F. Hofmann
L. F. Kelly
P. Krusche
M.-C. Laramee
K. Lheritier
G. Ligozio
A. Readie
L. Santos
T.E. Nichols
Janice Branson
C. Holmes
Show All
Source
Cite
Save
Citations (1)
Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study.
2014
Journal of The European Academy of Dermatology and Venereology
B. Sigurgeirsson
L. Kircik
O. Nemoto
I. Mikazans
S. Haemmerle
H.J. Thurston
Charis Papavassilis
H.B. Richards
Show All
Source
Cite
Save
Citations (10)
Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study
2013
British Journal of Dermatology
Kim Papp
R.G. Langley
B. Sigurgeirsson
Masatoshi Abe
D. R. Baker
P Konno
S. Haemmerle
H.J. Thurston
Charis Papavassilis
H.B. Richards
Show All
Source
Cite
Save
Citations (281)
1